Clinical TrialsSearch results
Number of results: 537
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- Efficacy of polymeric formula on outcomes in robotic pancreatectomy
- The patients who receive robotic pancreatectomy
- Takagi Kosei
- 2023-10-31
Not yet recruiting
- Effect of mouthwash on dentin hypersensitivity
- Dentin hypersensitivity
- Kei Takahashi
- 2023-10-12
Recruiting
- A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan
- Relapsed or Refractory T-cell Lymphoma
- Hayakawa Jin
- 2023-09-27
Recruiting
- A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE
- Systemic Lupus Erythematosus
- Otani Tetsuya
- 2023-09-14
Recruiting
- A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation
- Advanced/metastatic NSCLC with Exon 20 insertions and Uncommon/Single or Compound EGFR Mutations
- Dempke Wolfram
- 2023-09-12
Recruiting
- A Study of Zipalertinib and Chemotherapy Compared With Chemotherapy Alone in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion
- Locally advanced or metastatic nonsquamous NSCLC harboring EGFR exon 20 insertion mutations
- Dempke Wolfram
- 2023-09-12
No Longer Recruiting
- Microfoam Sclerotherapy for Venous Malformations
- venous malformation
- Hiroyasu Fujiwara
- 2023-08-18
Other
- Effects of hydrogen jelly on depressive symptoms and cognitive function
- Mild cognitive impairment, Depression in the elderly
- Takayuki Maruyama
- 2023-08-02
Other
- Effect of hydrogen-containing jelly on periodontal tissue
- Periodontitis
- Takayuki Maruyama
- 2023-08-02
Other
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With HR+/HER2- Metastatic Breast Cancer Who Have Received Endocrine Therapy
- HR+/HER2- inoperable, locally advanced, or metastatic breast cancer who have received prior ET
- Akiyama Masanao
- 2023-06-29